You are here: Home » Current Affairs » News » National
Meet GISAID, the open science database helping us make sense of Covid-19
Top headlines: Goldman downgrades Indian mkts, Asia to clock lowest growth
Business Standard

Six Indian cos working on Covid-19 vaccine; ramp up testing, say experts

As Covid-19 infects more than 1.9 million in the world and claims 1,26,000 lives, Indian scientists are also part of the global fight against the disease

Topics
Coronavirus | India | World Health Organization

BS Web Team & Agencies  |  New Delhi 



coronavirus, test
Generally, vaccines take several months to pass the different stages of testing, and then approvals also take time

Six Indian companies are working on a vaccine to control coronavirus, joining global efforts to find a quick prevention for it, a top Indian scientist said. 

Nearly 70 vaccine candidates' are being tested and at least three have moved to the human clinical trial stage, but a vaccine for the novel is unlikely to be ready for mass use before 2021.

Meanwhile, experts have warned that needs to "significantly ramp up" the number of tests done across the country to trace Covid-19 infection if the virus is to be contained in time.

While Zydus Cadila is working on two vaccines, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax are developing one vaccine each, Gagandeep Kang, executive director of the Translational Health Science and Technology Institute, Faridabad, told PTI.


Kang is also vice-chairperson of the Coalition for Epidemic Preparedness Innovations (CEPI), which noted in a recent study that the global vaccine R&D effort in response to the Covid-19 pandemic is unprecedented in terms of scale and speed.

Generally, vaccines take several months to pass the different stages of testing, and then approvals also take time. For Covid-19, we don't expect a vaccine to come in this year, agreed Rakesh Mishra, director of the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad.

Vaccine testing typically begins with animal and lab testing before going on to different stages of human testing. The human testing phase is composed of many phases, Sreekumar told PTI.

Phase one trials are small-scale, usually involving few participants, to assess whether the vaccine is safe for humans. Phase two trials often involve several hundred subjects, and mainly evaluate the efficacy of the vaccine against the disease, he said.


The final phase involves thousands of people to further assess the efficacy of the vaccine over a defined period of time, and can last several months, Sreekumar said. That is why we don't see a vaccine coming in at least a year from now.

Even after the vaccine is ready, he explained, there are a lot of challenges, including whether the vaccine is effective in all populations, and if it can be used for different strains of the novel coronavirus, which might start mutating as time passes.

There are lots of vaccines which are being tested for Covid-19, some of which are in the stage 1 clinical trial, Mishra added. But we still don't know how fast they will proceed towards a vaccine and they can take several months to reach any point, he said.

According to the (WHO), three vaccine candidates are in the clinical testing phase, meaning they are able to be tested on humans, while nearly 70 are in the preclinical phase -- either in lab testing or animal studies.


Though Kang named six companies, the WHO has listed only Zydus Cadila and Serum Institute from as among the global firms working on a Covid-19 vaccine.

The most advanced candidates have recently moved into clinical development, including mRNA-1273 from US-based biotechnology company Moderna, Ad5-nCoV from Chinese biopharma company CanSino Biologicals, and INO-4800 from American pharmaceuticals company Inovio.

Others in this list include LV-SMENP-DC and pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute in China.

Experts believe the genome sequencing of the new provided by scientists in China shows it shares 79 per cent of the same genetic material as severe acute respiratory syndrome (SARS) and 50 per cent of the same material as Middle East respiratory syndrome (MERS), a species of which infects humans, bats, and camels.


This allows developers to use groundwork already created in research for vaccines for those viruses.



needs to step up testing, experts warn

India needs to "significantly ramp up" the number of tests done across the country to trace Covid-19 infection if the virus is to be contained in time, experts said.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Thu, April 16 2020. 12:27 IST

RECOMMENDED FOR YOU

.